"Gut Microbiota –An Active Participant and Therapeutic Target for Cardiometabolic Disease"
Recent studies reveal a novel mechanistic link between intestinal microbiota and the development of cardiovascular disease (CVD). Dietary nutrients abundant in a Wester diet (e.g. choline, phosphatidylcholine, and carnitine) are acted upon by gut microbes to form, trimethylamine (TMA), which is then converted by host hepatic flavin monooxygenases to form the metabolite TMAO (trimethylamine-N-oxide). TMAO in animal model studies has been shown to promote atherosclerosis. Human clinical studies show TMAO strongly associates with incident risks for MI, stroke or death, and is generated in a gut microbiota -dependent fashion. More recent studies now show that the metaorganismal TMAO pathway is linked to both enhanced platelet reactivity and thrombosis potential. Studies presented suggest gut microbiota may participate in the pathogenesis of cardiometabolic diseases, thrombosis potential, and the gut microbiome may serve as a potential therapeutic target for the treatment and prevention of CVD.
Dr. Hazen (H-index 110) has published >400 peer-reviewed articles in basic and clinical journals alike. He has made numerous discoveries in atherosclerosis and inflammatory disease research, including chemically defining various oxidative processes operative during inflammation and atherosclerosis, and both the seminal discovery linking gut microbial pathways to cardiovascular disease (CVD) pathogenesis, and the development of non-lethal microbial enzyme inhibitors for the treatment of cardiometabolic diseases. His research impacts clinical practice, and both lays the foundation for FDA-cleared diagnostic tests in use worldwide, and ongoing CVD drug development efforts. Dr. Hazen is a member of the National Academy of Medicine, and a fellow of the American Association for the Advancement of Science